BLOG/🇺🇸United States··daily

All HHS Contracts — December 30, 2025

All HHS Contracts

11 total filings analysed

Executive Summary

HHS commits $405M across 11 contracts in 2025, with 45% ($182M) in top 3 awards to pharma manufacturing ($140M Chartwell RX) and IT services ($73M Peraton, $29M Sapient), signaling priorities in preparedness stockpiling and digital modernization. Five bullish signals on small business set-asides provide revenue visibility to 2029, with 60% average outlay execution in mature deals. Neutral signals dominate nonprofits/JVs, but option upside totals $200M+ warrants monitoring for growth.

Tracking the trend? Catch up on the prior All HHS Contracts digest from December 29, 2025.

Investment Signals(5)

  • Pharma manufacturing set-aside for antibiotics(HIGH)

    $140M fully obligated to Chartwell RX through Dec 2025 supports committed revenue amid HHS preparedness focus.

  • NIH IT/computing services expansion potential(HIGH)

    $27M obligated to Sapient with $90M option ceiling to 2029 indicates multi-year revenue ramp.

  • Small business IT payroll O&M lock-in(HIGH)

    $17M early outlay to Lyceum with $40M potential through 2029 via set-aside secures long-term HHS spend.

  • FDA pathology services steady execution(MEDIUM)

    $24M with 79% outlay to Toxicologic Pathology through Sep 2025 highlights reliable small business delivery.

  • IHS consulting for accreditation compliance(MEDIUM)

    $9M firm-fixed to Bryant SDB positions for tribal health support amid short 1-year window.

Risk Flags(3)

  • Execution[HIGH RISK]

    Firm-fixed-price structures across 5 contracts ($214M total) expose to cost overruns without adjustment.

  • Execution[MEDIUM RISK]

    Time-and-materials pricing in 4 contracts ($54M) risks labor hour/rate scrutiny and audits.

  • Market[MEDIUM RISK]

    Unexercised options ($200M+ potential) in 7 contracts vulnerable to HHS budget shifts.

Opportunities(3)

  • $200M+ in unexercised options across IT/health services contracts to 2029.

  • Small/SDB set-asides (6 of 11 contracts, $230M) favor follow-ons in preparedness/IT.

  • High outlay execution (avg 65%) in 2025-ending contracts signals closeout cash flows.

Sector Themes(3)

  • $144M (36%) in antibiotics/pathology/staffing underscores HHS ASPR/FDA antibiotic and medical readiness focus.

  • $114M (28%) across data centers, computing, payroll signals multi-year digitization push by NIH/PSC.

  • Ongoing CDC/NIH spend ($110M) in infrastructure/research despite neutral signals on nonprofits/JVs.

Watch List(3)

  • 👁

    {"entity"=>"Chartwell RX LLC", "reason"=>"Largest award ($140M, 35% total) fully obligated with $99M outlay; 2025 closeout pivotal.", "trigger"=>"Extension beyond Dec 2025 or new ASPR awards"}

  • 👁

    {"entity"=>"Lyceum Business Services, LLC", "reason"=>"$17M early outlay with $40M potential to 2029; newest high-upside set-aside.", "trigger"=>"Option exercises adding $23M by 2026"}

  • 👁

    {"entity"=>"Sapient Government Services, Inc.", "reason"=>"$27M obligated with $63M option expansion to 2029; rapid $13M outlay post-award.", "trigger"=>"NIH NLM funding for full $90M ceiling"}

Get daily alerts with 5 investment signals, 3 risk alerts, 3 opportunities and full AI analysis of all 11 filings

🇺🇸 More from United States

View all →